Skip to main
MDXG

MiMedx Group (MDXG) Stock Forecast & Price Target

MiMedx Group (MDXG) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 60%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

MiMedx Group is a leading provider of regenerative biomaterial products made from human amniotic membrane, birth tissues, and human skin & bone, with a proven track record of helping clinicians treat chronic wounds for over a decade. Despite recent challenges in the wound care market due to reimbursement changes and payment processes, the company has proactively implemented cost reduction initiatives and its CEO has taken a 20% salary reduction, positioning it for strong future growth in the wound care, surgical, and orthopedics markets with its best-in-class suite of clinical data and vertically integrated manufacturing infrastructure.

Bears say

MiMedx Group is facing challenges related to unique and complex reimbursement situations for their key market, leading to a decline in net sales in the first quarter of 2026. The company has implemented a restructuring and cost reduction plan, but this may only provide temporary relief and could have long-term impacts on their sales and margins. Additionally, they face risks related to tissue donorship, regulation of their products, and contracts with GPOs and IDNs, which could adversely impact their revenue and cash flow. However, with an established track record and strong clinical data, as well as opportunities for growth in the Advanced Surgical and international Wound Care segments, MiMedx may be able to weather the storm and see a return to solid, double-digit revenue growth in the long run.

MiMedx Group (MDXG) has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 60% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MiMedx Group and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MiMedx Group (MDXG) Forecast

Analysts have given MiMedx Group (MDXG) a Buy based on their latest research and market trends.

According to 5 analysts, MiMedx Group (MDXG) has a Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MiMedx Group (MDXG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.